- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06613503
Effectiveness of the AI-Supporter in Reducing Urinary Tract Infections
Testing the Effectiveness of the AI-Supporter in Reducing Urinary Tract Infections, Incontinence-associated Dermatitis and Caregiving Costs for Incontinence Patients
The "AI Supporter," an intelligent excretion management robot, leverages artificial intelligence-based vision recognition to autonomously detect and cleanse affected areas, followed by drying and changing the diaper, thereby reducing caregiver strain and enhancing care quality. This study aims to assess the efficacy of the "AI Supporter" in decreasing the incidence of urinary tract infections and incontinence-associated dermatitis among incontinent patients, in addition to exploring its cost-effectiveness.
Adopting an experimental (two groups) and longitudinal design, this research utilizes both convenience and random sampling strategies. The study anticipates recruiting 60 female subjects who have been confined to bed for more than three months with urinary and/or fecal incontinence. Participants will intermittently use the AI Supporter over a 14-day period. Measurement tools include routine urine analysis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: As Taiwan progresses medically, the aging demographic has become a significant challenge, leading to an escalation in the disabled population. The lack of caregiving manpower represents a critical bottleneck in the provision of long-term care. Diaper changing, a daily and labor-intensive task for caregivers, involves bending motions that pose a risk of musculoskeletal injuries. Consequently, the imperative development of automated caregiving technologies has emerged. The "AI Supporter," an intelligent excretion management robot, leverages artificial intelligence-based vision recognition to autonomously detect and cleanse affected areas, followed by drying and changing the diaper, thereby reducing caregiver strain and enhancing care quality.
Objective: This study aims to assess the efficacy of the "AI Supporter" in decreasing the incidence of urinary tract infections and incontinence-associated dermatitis among incontinent patients, in addition to exploring its cost-effectiveness.
Methods: Adopting an experimental (two groups) and longitudinal design, this research utilizes both convenience and random sampling strategies. Scheduled from November 2024 to October 2025 at a residential long-term care facility in Central Taiwan, the study anticipates recruiting 60 female subjects who have been confined to bed for more than three months with urinary and/or fecal incontinence. Participants will intermittently use the AI Supporter over a 14-day period. Measurement tools include routine urine analysis, incontinence-associated dermatitis rating scales, pressure sore assessments, skin pH measurements, caregiver hours, and cost analyses pertaining to diapers and the AI Supporter. The principal analytical method employed will be Generalized Estimating Equations (GEE), with statistical significance defined at p < 0.05.
Expected Outcomes: The AI Supporter is expected to significantly reduce the occurrence of urinary tract infections and incontinance-associated dermatitis in patients, concurrently alleviating caregiver workload and diminishing associated costs.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kwo-Chen Lee, ph.D
- Phone Number: 7102 886422053366
- Email: rubylee@mail.cmu.edu.tw
Study Contact Backup
- Name: Jing-ya Fu
- Phone Number: 7102 886422053366
Study Locations
-
-
-
Taichung, Taiwan
- Recruiting
- Rom A Master List, Extracted From This Organization'S Records.
-
Contact:
- Kwo chen Lee
- Phone Number: 886922351328
- Email: rubylee@mail.cmu.edu.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must have been bedridden for at least 3 months and have urinary and/or fecal incontinence.
- Female participants aged over 20 years old.
- Participants must be capable of wearing the AI-supporter device during the study period.
Exclusion Criteria:
- Participants with severe skin conditions unrelated to incontinence.
- Participants with current urinary tract infections or incontinence-associated dermatitis at the time of enrollment.
- Participants who are unable to provide informed consent or have a legal representative to do so.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: AI-supporter
Participants will use the AI-supporter for excretion detection, cleaning, and drying processes.
|
rticipants in the experimental group will use the AI-supporter, an intelligent excretion management robot.
This device utilizes AI-driven visual recognition technology to automatically detect urine and feces, followed by a cleaning and drying process.
When the AI-supporter detects excretion, it activates an automated sequence that washes, dries, and sanitizes the perineal area without requiring the caregiver to remove the diaper.
The AI-supporter also records relevant data, such as the time, frequency, and weight of excretion, for further analysis.
This intervention is designed to reduce the incidence of urinary tract infections (UTIs) and incontinence-associated dermatitis (IAD), as well as lessen the workload for caregivers
Other Names:
|
|
No Intervention: Traditional Diapers
Participants will use theTraditional Diapers for excretion detection, cleaning, and drying processes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
white blood cells
Time Frame: 14 days after intervention
|
urine analysis
|
14 days after intervention
|
|
Bacterial count
Time Frame: 14 days after intervention
|
urine analysis
|
14 days after intervention
|
Collaborators and Investigators
Investigators
- Study Director: Kwo-Chen Lee, ph.D, 011+886+4+22053366#7102
Publications and helpful links
General Publications
- Buckingham KW, Berg RW. Etiologic factors in diaper dermatitis: the role of feces. Pediatr Dermatol. 1986 Feb;3(2):107-12. doi: 10.1111/j.1525-1470.1986.tb00499.x.
- Borchert K, Bliss DZ, Savik K, Radosevich DM. The incontinence-associated dermatitis and its severity instrument: development and validation. J Wound Ostomy Continence Nurs. 2010 Sep-Oct;37(5):527-35. doi: 10.1097/WON.0b013e3181edac3e.
- Fader M, Clarke-O'Neill S, Cook D, Dean G, Brooks R, Cottenden A, Malone-Lee J. Management of night-time urinary incontinence in residential settings for older people: an investigation into the effects of different pad changing regimes on skin health. J Clin Nurs. 2003 May;12(3):374-86. doi: 10.1046/j.1365-2702.2003.00731.x.
- Ferreira M, Abbade L, Bocchi SCM, Miot HA, Boas PV, Guimaraes HQCP. Incontinence-associated dermatitis in elderly patients: prevalence and risk factors. Rev Bras Enferm. 2020;73 Suppl 3:e20180475. doi: 10.1590/0034-7167-2018-0475. Epub 2020 Jul 13. English, Portuguese.
- Francis K, Pang SM, Cohen B, Salter H, Homel P. Disposable Versus Reusable Absorbent Underpads for Prevention of Hospital-Acquired Incontinence-Associated Dermatitis and Pressure Injuries. J Wound Ostomy Continence Nurs. 2017 Jul/Aug;44(4):374-379. doi: 10.1097/WON.0000000000000337.
- Gray M. Optimal management of incontinence-associated dermatitis in the elderly. Am J Clin Dermatol. 2010;11(3):201-10. doi: 10.2165/11311010-000000000-00000.
- Hachem JP, Crumrine D, Fluhr J, Brown BE, Feingold KR, Elias PM. pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion. J Invest Dermatol. 2003 Aug;121(2):345-53. doi: 10.1046/j.1523-1747.2003.12365.x.
- Hahnel E, Blume-Peytavi U, Trojahn C, Kottner J. Associations between skin barrier characteristics, skin conditions and health of aged nursing home residents: a multi-center prevalence and correlational study. BMC Geriatr. 2017 Nov 13;17(1):263. doi: 10.1186/s12877-017-0655-5.
- Kayser SA, Phipps L, VanGilder CA, Lachenbruch C. Examining Prevalence and Risk Factors of Incontinence-Associated Dermatitis Using the International Pressure Ulcer Prevalence Survey. J Wound Ostomy Continence Nurs. 2019 Jul/Aug;46(4):285-290. doi: 10.1097/WON.0000000000000548.
- Minematsu T, Yamamoto Y, Nagase T, Naito A, Takehara K, Iizaka S, Komagata K, Huang L, Nakagami G, Akase T, Oe M, Yoshimura K, Ishizuka T, Sugama J, Sanada H. Aging enhances maceration-induced ultrastructural alteration of the epidermis and impairment of skin barrier function. J Dermatol Sci. 2011 Jun;62(3):160-8. doi: 10.1016/j.jdermsci.2011.03.005. Epub 2011 Mar 23.
- Mugita Y, Koudounas S, Nakagami G, Weller C, Sanada H. Assessing absorbent products' effectiveness for the prevention and management of incontinence-associated dermatitis caused by urinary, faecal or double adult incontinence: A systematic review. J Tissue Viability. 2021 Nov;30(4):599-607. doi: 10.1016/j.jtv.2021.07.002. Epub 2021 Jul 13.
- Musa MK, Saga S, Blekken LE, Harris R, Goodman C, Norton C. The Prevalence, Incidence, and Correlates of Fecal Incontinence Among Older People Residing in Care Homes: A Systematic Review. J Am Med Dir Assoc. 2019 Aug;20(8):956-962.e8. doi: 10.1016/j.jamda.2019.03.033. Epub 2019 May 23.
- Nix DH. Validity and reliability of the Perineal Assessment Tool. Ostomy Wound Manage. 2002 Feb;48(2):43-6, 48-9.
- Shin YS, Kim HJ, Moon NK, Ahn YH, Kim KO. The effects of uncoated paper on skin moisture and transepidermal water loss in bedridden patients. J Clin Nurs. 2012 Sep;21(17-18):2469-76. doi: 10.1111/j.1365-2702.2012.04160.x.
- Sugama J, Sanada H, Shigeta Y, Nakagami G, Konya C. Efficacy of an improved absorbent pad on incontinence-associated dermatitis in older women: cluster randomized controlled trial. BMC Geriatr. 2012 May 29;12:22. doi: 10.1186/1471-2318-12-22.
- Yeomans A, Davitt M, Peters CA, Pastuszek C, Cobb S. Efficacy of chlorhexidine gluconate use in the prevention of perirectal infections in patients with acute leukemia. Oncol Nurs Forum. 1991 Sep-Oct;18(7):1207-13.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMUH113-REC3-109
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Tract Infection
-
Angela HUTTNERUniversity Hospital, GenevaEnrolling by invitationUrinary Tract Infection(UTI) | UTI - Urinary Tract Infection | Urinary Tract Infection, RecurrentSwitzerland, Netherlands, Germany
-
Gloucestershire Hospitals NHS Foundation TrustWithdrawnCatheter Infection | Urinary Tract Infection in Pregnancy | Urinary Tract Infection Following Delivery
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedUrinary Tract Infection | Recurrent Urinary Tract InfectionCanada
-
National Institute of Allergy and Infectious Diseases...TerminatedUrinary Tract InfectionUnited States
-
University Of PerugiaUnknownUrinary Tract Infection
-
NanovibronixShaare Zedek Medical CenterUnknownUrinary Tract InfectionIsrael
-
Hadassah Medical OrganizationUnknown
-
National Center for Complementary and Integrative...Office of Dietary Supplements (ODS)UnknownUrinary Tract InfectionCanada
-
Impatients N.V. trading as myTomorrowsInmunotek S.L.No longer availableUrinary Tract Infections | Bladder Infection | Recurrent Urinary Tract Infection | Urinary Tract Infection Bacterial | Chronic Urinary Tract InfectionCzechia, Denmark, Serbia, France, Germany, Turkey, Belgium, Finland, Luxembourg, Netherlands, Norway, Romania, Slovakia, Slovenia, Sweden
-
Hospital de Clinicas de Porto AlegreUnknownUrinary Tract Infection | Respiratory Tract InfectionBrazil
Clinical Trials on AI-supporter
-
University of ArkansasCompletedSuicidal Ideation | Suicide, Attempted | Mental Health IssueUnited States
-
National Taiwan University HospitalUnknownEvaluation of Wrist Muscle StrengthTaiwan
-
University of WashingtonCompletedStress | Stress Disorders, Post-Traumatic | Sexual Violence | Sexual Assault | Help-Seeking Behavior | Social Interaction | Helping Behavior | Relationship, SocialUnited States
-
Wake Forest University Health SciencesCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1-infection | Antenatal CareMalawi
-
Cheng-Hsin General HospitalEnrolling by invitation
-
University of ManchesterUniversity of CambridgeRecruitingPrimary Care | Artificial Intelligence (AI)United Kingdom
-
Shandong UniversityCompletedArtificial Intelligence | Optical Enhancement Endoscopy | Magnifying EndoscopyChina
-
Shanghai Jiao Tong University Affiliated Sixth...RecruitingAcute Ischemic Stroke | CT Angiography | Endovascular Thrombectomy | Artificial Intelligence (AI)China
-
Duke UniversityNational Cancer Institute (NCI)Not yet recruitingBreast Cancer, Hormone Receptor Positive, Aromatase Inhibitor-Associated Arthralgia